In summary, we conclude that EGFR sensitizing mutations is not a significant prognostic marker for patients with non-metastatic NSCLC undergoing definitive thoracic radiotherapy, with or without chemotherapy. Here, EGFR is linked to non-small cell lung carcinoma.